Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarucizumab for Dabigatran Reversal Case Series
NCT03343704Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2018
- Primary completion
- Jul 2020
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
A Phase 3 trial of idarucizumab in hemorrhage, sponsored by Boehringer Ingelheim. Started Mar 2018; status: completed.
02
Drugs
idarucizumab
03
Conditions
hemorrhage
Beyond the preview
Go deeper on NCT03343704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03343704.